platelets in health & disease - aj
DESCRIPTION
TRANSCRIPT
PLATELETS IN HEALTH AND DISEASE
Dr.AnuPriya J
SCHEME
• Introduction • History • Formation • Structure • Properties • Functions• Role in hemostasis• Platelet function tests• Antiplatelet drugs • Platelet disorders • Transfusion
Introduction
• Blood is a complex fluid consisting of plasma and of formed elements – red blood cells, white blood cells & platelets.
• Platelets are small, anuclear, cytoplasmic fragments of megakaryocytes
• Normal platelet count – 1.5 to 4 L / mm3 of blood
• Platelets survive in circulation for about 8-10 days
• Removal -by the mononuclear phagocyte system -spleen plays a major role
• Half life – about 5 days
Introduction
History
• Hewson - in 1780 - very small undefined particles in blood.
• Max Schultze in 1865 - these particles must be degenerate and disintegrated leukocytes – as they showed a granular appearance.
• Riess in 1872 and Laptschinski in 1874 - leucocytes - mainly during infectious diseases – are the origin of the Schultze's corpuscles.
• George Hayem between the years 1878 and 1879 - related to erythrocytes - considered as their precursors - the term “haematoblasts”
• Neumann -1880 - stated they were artifacts derived from red cells following an incorrect technique of venipuncture .
History
• Giulio Bizzozzero - the first - in 1882 - clearly establish the significance of the particles- the third morphological element of blood, totally unrelated to white and red cells - gave a more precise description
• Bizzozzero named these elements “piastrine”, i.e. small plates
• Wright - Between 1906 and 1910 - identified bone marrow megakaryocytes as precursors of blood platelets – first to use the term “platelets”
History
• The invention of the aggregometer by Born in 1962 provided a valuable instrument to study platelet function and responsiveness to agonists
• In 1964, David-Ferreira published the first paper concerning platelet ultrastructure analyzed by means of electron microscopy.
History
• The late 20th century - the definition and characterization of many platelet receptors- the analysis of molecular mechanisms involved in signal
transduction - the introduction of anti-platelet treatments
• Recent – collection, storage & transfusion
History
Formation
Pluripotent stem cellsCommitted stem cells
CFU-MegaMegakaryoblast
Basophil megakaryocyteGranular megakaryocyteMature megakaryocyte
Platelets
Thrombopoiesis
CFU - GEMM
CFU-MegE
CFU-Mega
TPO
Formation • Thrombopoiesis – formation of platelets
• Regulated by - Thrombopoietin- Interleukin (IL-1,IL-3,IL-6,IL-11)- GM-CSF
• Each megakaryocyte produces between 1,000 to 3,000 platelets during its lifetime.
• An average of 1011 platelets are produced daily in a healthy adult.
•Small, granulated, anuclear, discoid
•Diameter - 2 to 3 μm
•Volume - 8 fl
•Size - One fourth of red cells
Structure
Granular contents
VWF
Properties
Adhesion
Activation& Release
Aggregation
Functions
• Temporary hemostasis• Blood coagulation• Clot retraction• Phagocytosis• Storage & transport• Wound healing & Vascular growth
Role in hemostasis
Role in hemostasis
Adhesion
• VWF – GpIb/IX/V • Collagen – GpIa/IIa• Fibronectin & Laminin – GpIc/IIa• Collagen – GpVI
Role in hemostasis
Role in hemostasis
Activation & Release Platelet agonists bind with specific membrane receptors ↓ G protein activation ↓ Activation of Phospholipase C ↓ Membrane inositol phospholipids ↓ IP3 , DAG
Role in hemostasis
IP3 • A calcium ionophore
• Causes calcium to enter the cytosol from the dense tubular system ( an internal platelet reservoir) and from the platelet exterior
• A rising cytosolic calcium concentration
Role in hemostasis
Calcium Rising cytosolic calcium concentration ↓ Activation of myosin light chain kinase ↓ Phosphorylation of myosin light chain ↓ Reorientation of cytoskeletal proteins ↓ Platelet shape change,secretion and contraction
Role in hemostasis
Calcium
• Contraction of the actin microfilaments – movement of granules to the open canalicular system – release
• Calcium and platelet agonists also activates phospholipase A2
Role in hemostasis
Activation & Release G protein activation and calcium ↓ Activation of Phospholipase A2
↓ Membrane phosphatidylcholine ↓ Arachidonic acid ↓COX PGH2 ↓ Thromboxane synthase TXA2
Role in hemostasis
• PGH2 – a cofactor enhancing the ability of collagen to function as a platelet agonist
• TXA2 – binds to a specific platelet membrane receptor – resultant activation of Phospholipase C – amplification of platelet activation through further generation of IP3,DAG
Role in hemostasis
• Activated platelets change shape from disc to tiny sphere with numerous projecting pseudopods
• Activated platelets exocytose the contents of their dense storage granules and alpha granules
• Platelet activating factor (PAF) – cytokine – neutrophils, monocytes & platelets ; produced from membrane lipids; acts via G proteins
Role in hemostasis
• Locally damaged red cells also release ADP which further activates the platelets
• Thrombospondin and Thrombonectin – facilitate contractile system activity – promote exocytosis of granular contents.
• Thrombospondin – binds to fibrinogen n GP IV receptor secondary phase of aggregation – larger, firmer aggregates
Role in hemostasis
Role in hemostasis
Role in hemostasis
Role in hemostasis
• Platelet activation – increased platelet coagulant activity
• Synthesize coagulation factor V
• Platelet phospholipids - Platelet factor 3 and 4 - accelerate the formation of Va, VIIIa
• Va – conversion of prothrombin to thrombin
• Platelets play a major role in formation of intrinsic prothrombin activator – clot formation
Role in hemostasis
XII XIIa
XI XIa
IXaIX
X Xa
VIIIaVIII
VII VIIa
X
Prothrombin
Intrinsic Pathway Extrinsic Pathway
VaV
Thrombin
Fibrinogen Fibrin monomer
Blood Coagulation Cascade
Collagen, HMW Kininogen, Kallikrein
↓
HMW Kininogen
Platelet phospholipidsCalcium
Platelet phospholipidsCalcium
Calcium
XIIIaXIIIStable fibrin polymer(clot)
Release of tissue factor(Tissue thromboplastin)
Platelet phospholipidsCalcium
Role in hemostasis
The activated platelets incorporated in the clot rearrange and contract their intracellular actin/myosin cytoskeleton.
The intracellular actin network - internal part of GpIIb/IIIa fibrinogen receptor.
The external part of GpIIb/IIIa - the fibrin network of the clot
As a result of platelet contractile force on the fibrin network, the formed clot will compact on itself and hence reduce its total volume.
Role in hemostasis Clot retraction
Platelet factor 4 Platelet derived growth factor(PDGF) Transforming growth factor β
• Chemoattractants for WBCs, Smooth muscle cells & fibroblasts.
• Activate these cells and accelerate wound healing.• PDGF – Potent mitogen for vascular smooth muscle.
Role in hemostasis Wound healing
Platelet function tests
• Platelet count• Bleeding time• Platelet aggregation test• Platelet adhesiveness test• Clot retraction time
Antiplatelet drugs
Bernard-Soulier Syndrome(Giant Platelet Syndrome)
• Discovered by Jean Bernard and Jean-Pierre Soulier, 1948
• Abnormality of the platelet glycoprotein Ib-IX-V complex, receptor for vWF – platelets cannot adhere
• Inherited in autosomal recessive manner
• Large platelets on peripheral blood smear• Normal count, Prolonged bleeding time• Decreased or absent glass bead retention• Platelets aggregate wt physiological agonists but fail to
aggregate wt ristocetin (similar to Von Willebrand disease)
Glanzmann's thrombasthenia
• Platelets lack GPIIb/IIIa; hence, no fibrinogen binding can occur
• Inherited in autosomal recessive manner
• Normal morphology and count • Platelets less able to aggregate ; defective clot retraction • Bleeding time is significantly prolonged• Platelets do not aggregate with all aggregating agents but
they aggregate with ristocetin.
Granule defects
• δ storage pool disease – dense body deficiency• α granule deficiency – grey platelet syndrome• αδ storage pool disease
• δ storage pool disease- Autosomal dominant- Absence of dense bodies- Seen in association with certain inherited disorders
Gray platelet syndrome
• A rare condition caused by a reduction or absence of the platelet alpha granules, or of the proteins contained in these granules
Pseudo gray platelet syndrome• Platelets in blood collected into EDTA appear gray and
agranular compared with platelets from citrated blood.• EDTA-exposed platelets show extensive activation, with loss of
storage granule contents and pseudopod formation
Von Willebrand disease (vWD)• Most common hereditary coagulation abnormality • Arises from a qualitative or quantitative deficiency of vWF• Hereditary – type 1, type 2, type 3.• Acquired
• Normal count, Prolonged bleeding time• Deficiency of factor VIII activity in the plasma• Platelets aggregate wt physiological agonists but fail to
aggregate wt ristocetin• Desmopressin – type 1 and 2 - stimulates release of VWF from
Weibel-Palade bodies of endothelial cells• vWF replacement therapy – type 3 disease
Thrombocytopenia• Pseudothrombocytopenia
• Decrease Production– Marrow Damage
• Aplasia• Drugs• Malignancy• Radiation
– Congenital Defects– Ineffective Production
• B12, Folic Acid Def
• Increase DestructionNon Immune• Disseminated Intravascular Coagulation• Thrombotic Thrombocytopenic Purpura• HELLP syndrome
Immune• Idiopathic Thrombocytopenic Purpura• Heparin Induced Thrombocytopenia• SLE, AIDS• Thrombotic Thrombocytopenic Purpura• Neonatal • Post transfusion
Thrombocytopenia
Idiopathic Thrombocytopenic Purpura
• Autoimmune• IgG autoantibody mediated platelet destruction• Thrombocytopenia with normal or increased number of
megakaryocytes • Diagnosis of exclusion• Childhood/Adult onset• Children – Acute; H/O viral infection , self-limiting• Adults – F > M; Chronic; longer course • 80% respond to Oral prednisolone – 3 months – if no
response – Splenectomy• Intravenous immunoglobulin or Immunosuppressive drugs
Dengue hemorrhagic fever
• Characterized by severe thrombocytopenia with bleeding manifestations
• Severity depends on the dengue virus subtype• Concomitant infection with more than one subtype• Dengue virus 2 – most severe – direct binding,
ultramicroscopic changes• Cytotoxic factor ; increased proinflammatory cytokines• Plasma leakage – decreased plasma proteins – decreased
fibrinogen
• PLATELET TRANSFUSION• FRESH FROZEN PLASMA
Transfusion
• Platelets collected by apheresis – intermittent/continuous flow cell separator.
• Single donor / Random donor platelet concentrate• Storage - 20-24ᵒ C under constant agitation – 5 days• Neither group specific or Rh specific – cross matching not
needed• Indications – thrombocytopenia • Contraindications – Immune mediated thrombocytopenia
Post transfusion
• 5-7 days after transfusion• Allo antibodies
• Anti-P1A1 [Antigen located on gp IIIa subunit]• Anti-Baka (Leka) [Antigen located on gp IIb subunit]
• Self – limiting ; 3-6 weeks
• High dose intravenous immunoglobulin – treatment of choice
References
• Boron & Boulpaep - Medical Physiology, 2nd Edition • Ganong's Review Of Medical Physiology, 24th Edition• Best & Taylor's Physiological Basis Of Medical Practice, 13/ E.• Dacie And Lewis Practical Haematology 11th Edition• de Gruchy's Clinical Haematology In Medical Practice, 5th Ed• Arthropod borne viral diseases – Current status and research
– D.Raghunath Rao, C.Durga Rao• Textbook of Medical Physiology G K Pal 2 E• Internet references
• Alfred Donne -1842 «globulin du chyle» (that is to say small globules derived from plasma) a sort of small globular, pale, opaline corpuscles visible in blood.
• Later described by Beale in 1850 as particles of «germinal matter» and by Zimmermann in 1860 as «small corpuscles»
Role in hemostasis
Clot retraction After the clot has been formed, the activated platelets
incorporated in the clot rearrange and contract their intracellular actin/myosin cytoskeleton.
The intracellular actin network is connected to the internal part of the integrin αIIbβ3 fibrinogen receptor. Following coagulation, the external part of αIIbβ3 will have bound to the fibrin network of the clot, and therefore, as a result of platelet contractile force on the fibrin network, the formed clot will compact on itself and hence reduce its total volume.
The mechanism is termed clot retraction.
Role in hemostasis